About us Pricing ContactSubscribe

P

Peter H. O’Donnell

University of Chicago Medical CenterORCID https://orcid.org/0000-0003-2650-0049

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

The Lancet Oncology20171,329 citations

Peter H. O’Donnell · Scinovex